HUP0204126A3 - Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one, process for their preparation and pharmaceutical compositions containing them - Google Patents

Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HUP0204126A3
HUP0204126A3 HU0204126A HUP0204126A HUP0204126A3 HU P0204126 A3 HUP0204126 A3 HU P0204126A3 HU 0204126 A HU0204126 A HU 0204126A HU P0204126 A HUP0204126 A HU P0204126A HU P0204126 A3 HUP0204126 A3 HU P0204126A3
Authority
HU
Hungary
Prior art keywords
pseudopolymorph
benzopyran
piperidinyl
chlorophenyl
dihydroxy
Prior art date
Application number
HU0204126A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of HUP0204126A2 publication Critical patent/HUP0204126A2/hu
Publication of HUP0204126A3 publication Critical patent/HUP0204126A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Stereophonic System (AREA)
  • Inorganic Insulating Materials (AREA)
HU0204126A 2000-01-18 2001-01-08 Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one, process for their preparation and pharmaceutical compositions containing them HUP0204126A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48471700A 2000-01-18 2000-01-18
PCT/US2001/000519 WO2001053293A1 (en) 2000-01-18 2001-01-08 Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one

Publications (2)

Publication Number Publication Date
HUP0204126A2 HUP0204126A2 (hu) 2003-04-28
HUP0204126A3 true HUP0204126A3 (en) 2006-02-28

Family

ID=23925305

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204126A HUP0204126A3 (en) 2000-01-18 2001-01-08 Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one, process for their preparation and pharmaceutical compositions containing them

Country Status (26)

Country Link
EP (1) EP1259507B1 (hu)
JP (1) JP2003520797A (hu)
KR (1) KR100806464B1 (hu)
CN (1) CN1174977C (hu)
AT (1) ATE273303T1 (hu)
AU (1) AU2001226346A1 (hu)
BR (1) BR0107726A (hu)
CA (1) CA2397593C (hu)
CZ (1) CZ301195B6 (hu)
DE (1) DE60104822T2 (hu)
DK (1) DK1259507T3 (hu)
EA (1) EA005247B1 (hu)
ES (1) ES2222332T3 (hu)
HU (1) HUP0204126A3 (hu)
IL (2) IL150638A0 (hu)
MX (1) MXPA02007005A (hu)
NO (1) NO322572B1 (hu)
NZ (1) NZ520280A (hu)
PL (1) PL200696B1 (hu)
PT (1) PT1259507E (hu)
SI (1) SI1259507T1 (hu)
SK (1) SK287404B6 (hu)
TR (1) TR200402036T4 (hu)
TW (1) TWI284129B (hu)
WO (1) WO2001053293A1 (hu)
ZA (1) ZA200205639B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109803684B (zh) 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
EP4218820A3 (en) 2017-03-16 2023-09-20 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (hu) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5908934A (en) * 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs

Also Published As

Publication number Publication date
ES2222332T3 (es) 2005-02-01
HUP0204126A2 (hu) 2003-04-28
PL356165A1 (en) 2004-06-14
SK287404B6 (sk) 2010-09-07
EP1259507B1 (en) 2004-08-11
CZ301195B6 (cs) 2009-12-02
EA005247B1 (ru) 2004-12-30
TR200402036T4 (tr) 2004-10-21
DK1259507T3 (da) 2004-11-01
PL200696B1 (pl) 2009-01-30
CA2397593C (en) 2009-11-10
WO2001053293A1 (en) 2001-07-26
CZ20022466A3 (cs) 2002-11-13
NO322572B1 (no) 2006-10-30
TWI284129B (en) 2007-07-21
JP2003520797A (ja) 2003-07-08
MXPA02007005A (es) 2004-09-06
PT1259507E (pt) 2004-12-31
CA2397593A1 (en) 2001-07-26
DE60104822D1 (de) 2004-09-16
IL150638A0 (en) 2003-02-12
IL150638A (en) 2009-06-15
KR20020069361A (ko) 2002-08-30
DE60104822T2 (de) 2005-09-01
ZA200205639B (en) 2003-10-15
BR0107726A (pt) 2002-10-01
SI1259507T1 (en) 2005-02-28
SK10362002A3 (sk) 2003-01-09
KR100806464B1 (ko) 2008-02-21
AU2001226346A1 (en) 2001-07-31
NO20023386D0 (no) 2002-07-12
NO20023386L (no) 2002-09-12
NZ520280A (en) 2004-04-30
EP1259507A1 (en) 2002-11-27
CN1174977C (zh) 2004-11-10
ATE273303T1 (de) 2004-08-15
CN1395576A (zh) 2003-02-05
EA200200775A1 (ru) 2002-12-26

Similar Documents

Publication Publication Date Title
HUP0204515A3 (en) 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0302519A3 (en) Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
PL355844A1 (en) Novel pharmaceutical compositions of anti-tubrcular drugs and process for their preparation
HUP0204410A3 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203316A3 (en) Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201516A3 (en) 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203140A3 (en) Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201753A3 (en) Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203184A3 (en) Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0302130A3 (en) Combination pharmaceutical compositions and process for their preparation
PL352293A1 (en) Derivatives of purine, method of making same and pharmaceutical compositions containing these derivatives
HUP0202731A3 (en) O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0105481A3 (en) Pharmaceutical compositions containing clarithromycin and process for their preparation and their use
HUP0301080A3 (en) Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0103004A3 (en) Substituted imidazo[1,2a]azines as selective inhibitors of cox-2, process for their preparation and pharmaceutical compositions containing them
AU2001256570A1 (en) Novel anticancer compounds: process for their preparation and pharmaceutical compositions containing them
HUP0300389A3 (en) Crystalline form ii of cabergoline, process for its preparation and pharmaceutical compositions containing it
HUP0400317A3 (en) Beta-carboline derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0402282A3 (en) Triazolo[1,5a] quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0204001A3 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0303361A3 (en) Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0102895A3 (en) Cyclopentanone dihydropyridine derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
HUP0204126A3 (en) Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one, process for their preparation and pharmaceutical compositions containing them
HUP0200913A3 (en) Isoindoindololone derivatives process for their preparation and pharmaceutical compositions containing them
HUP0204297A3 (en) Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one-hydrochloride, process for its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: DR. LANG TIVADARNE, S.B.G. & K. SZABADALMI UEG, HU

FH92 Termination of representative

Representative=s name: BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVI, HU

GB9A Succession in title

Owner name: AVENTISUB II INC., US

Free format text: FORMER OWNER(S): AVENTIS PHARMACEUTICALS INC., US; AVENTIS HOLDINGS INC., US; HMR PHARMA, INC., US

FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished